Cargando…
Multi-Sensor Approach for the Monitoring of Halitosis Treatment via Lactobacillus brevis (CD2)—Containing Lozenges—A Randomized, Double-Blind Placebo-Controlled Clinical Trial
The aim of this randomized clinical trial was to evaluate whether a recently described multi-sensor approach called BIONOTE(®) is accurate enough to verify the efficacy of treatment of patients with halitosis. A treatment with Lactobacillus brevis (CD2)–containing lozenges, compared with placebo was...
Autores principales: | Marchetti, Enrico, Tecco, Simona, Santonico, Marco, Vernile, Chiara, Ciciarelli, Daniele, Tarantino, Ester, Marzo, Giuseppe, Pennazza, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570386/ https://www.ncbi.nlm.nih.gov/pubmed/26266414 http://dx.doi.org/10.3390/s150819583 |
Ejemplares similares
-
Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren
por: Campus, Guglielmo, et al.
Publicado: (2013) -
Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation
por: Sharma, Atul, et al.
Publicado: (2017) -
Effect of Lactobacillus brevis CD2 containing lozenges and plaque pH and cariogenic bacteria in diabetic children: a randomised clinical trial
por: Lai, Stefano, et al.
Publicado: (2020) -
Attenuating effect of Lactobacillus brevis G101 on the MSG symptom complex in a double-blind, placebo-controlled study
por: Kim, Dong-Hyun, et al.
Publicado: (2015) -
The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial
por: Murakami, Katsumi, et al.
Publicado: (2012)